London
· Delayed Price · Currency is GBP · Price in USD Moderna Statistics
Total Valuation
Moderna has a market cap or net worth of GBP 7.91 billion. The enterprise value is 1.32 billion.
| Market Cap | 7.91B |
| Enterprise Value | 1.32B |
Important Dates
The next estimated earnings date is Thursday, May 1, 2025.
| Earnings Date | May 1, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.52% |
| Shares Change (QoQ) | -3.51% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 360.75M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.06 |
| PB Ratio | 0.91 |
| P/TBV Ratio | 0.92 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.46 |
| EV / Sales | 0.54 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.41 |
Financial Position
The company has a current ratio of 3.67, with a Debt / Equity ratio of 0.07.
| Current Ratio | 3.67 |
| Quick Ratio | 3.45 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.18 |
| Interest Coverage | -164.38 |
Financial Efficiency
Return on equity (ROE) is -28.77% and return on invested capital (ROIC) is -18.44%.
| Return on Equity (ROE) | -28.77% |
| Return on Assets (ROA) | -15.14% |
| Return on Invested Capital (ROIC) | -18.44% |
| Return on Capital Employed (ROCE) | -33.05% |
| Revenue Per Employee | 445,659 |
| Profits Per Employee | -490,417 |
| Employee Count | 5,800 |
| Asset Turnover | 0.20 |
| Inventory Turnover | 37.66 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -74.41% in the last 52 weeks. The beta is 2.23, so Moderna's price volatility has been higher than the market average.
| Beta (5Y) | 2.23 |
| 52-Week Price Change | -74.41% |
| 50-Day Moving Average | 30.85 |
| 200-Day Moving Average | 52.83 |
| Relative Strength Index (RSI) | 46.75 |
| Average Volume (20 Days) | 45,065 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 5.25 |
Income Statement
In the last 12 months, Moderna had revenue of GBP 2.58 billion and -2.84 billion in losses. Loss per share was -7.41.
| Revenue | 2.58B |
| Gross Profit | -2.21B |
| Operating Income | -3.15B |
| Pretax Income | -2.88B |
| Net Income | -2.84B |
| EBITDA | -3.00B |
| EBIT | -3.15B |
| Loss Per Share | -7.41 |
Balance Sheet
The company has 5.61 billion in cash and 596.68 million in debt, giving a net cash position of 7.01 billion.
| Cash & Cash Equivalents | 5.61B |
| Total Debt | 596.68M |
| Net Cash | 7.01B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 8.71B |
| Book Value Per Share | 22.56 |
| Working Capital | 4.71B |
Cash Flow
In the last 12 months, operating cash flow was -2.40 billion and capital expenditures -839.51 million, giving a free cash flow of -3.24 billion.
| Operating Cash Flow | -2.40B |
| Capital Expenditures | -839.51M |
| Free Cash Flow | -3.24B |
| FCF Per Share | n/a |
Margins
Gross margin is -85.63%, with operating and profit margins of -121.91% and -110.04%.
| Gross Margin | -85.63% |
| Operating Margin | -121.91% |
| Pretax Margin | -111.46% |
| Profit Margin | -110.04% |
| EBITDA Margin | -116.07% |
| EBIT Margin | -121.91% |
| FCF Margin | n/a |
Dividends & Yields
Moderna does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.52% |
| Shareholder Yield | -0.52% |
| Earnings Yield | -35.97% |
| FCF Yield | -40.97% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Moderna has an Altman Z-Score of 7.29.
| Altman Z-Score | 7.29 |
| Piotroski F-Score | n/a |